Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Returns Ride Rollercoaster Into Mid-Year As More Biopharmas Take The Plunge

Executive Summary

Returns for the 36 biopharma firms that went public in the first half of 2018 – including 14 in June alone – averaged 20.9%, stabilizing after a dip earlier in the year. But while drug developer returns have been on a rollercoaster ride, they're doing better than broader stock indices.

Advertisement

Related Content

IPO Update: August Had A Slow Start, But New US Filings Hint At Busy September
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset
IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First
IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?
Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
Liquidia Technologies Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel